Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: A simulation study

IEEE Transactions on Biomedical Engineering

Volumn 50, Issue 2, 2003, Pages 168-177

  Cimponeriu, Adrian ^a   Starmer, C Frank ^b   Bezerianos, Anastasios ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antiarrhythmic drugs; Ischemia; Reentry; Sodium blockade; Vulnerable period

Indexed keywords

COMPUTER SIMULATION; DISEASES; DRUG THERAPY; MATHEMATICAL MODELS; TISSUE;

ISCHEMIC MODULATION;

BIOMEDICAL ENGINEERING;

ANTIARRHYTHMIC AGENT;

ANALYSIS; ARRHYTHMOGENESIS; ARTICLE; DISEASE CLASSIFICATION; DISEASE SIMULATION; DRUG BINDING AND TRANSPORT; DRUG SAFETY; HEART ARRHYTHMIA; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE EXCITABILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REFRACTORY PERIOD; HEART PROARRHYTHMIA; HYPOTHESIS; MATHEMATICAL MODEL; SODIUM TRANSPORT;

ACTION POTENTIALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; COMPUTER SIMULATION; HEART; HEART CONDUCTION SYSTEM; HUMANS; ION CHANNEL GATING; MEMBRANE POTENTIALS; MODELS, CARDIOVASCULAR; MODELS, NEUROLOGICAL; MYOCARDIAL ISCHEMIA; SENSITIVITY AND SPECIFICITY; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; TACHYCARDIA;

EID: 0242500962     PISSN: 00189294     EISSN: None     Source Type: Journal    
DOI: 10.1109/TBME.2002.807656     Document Type: Article

References (29)

1. L. P. Ferris, B. G. King, P. W. Spence, and B. H. Williams, "Effect of electric shock on the heart," Elect. Eng., vol. 55, pp. 489-515, 1936.
2. C. J. Wiggers and R. Wegria, "Ventricular fibrillation due to single localized induction and condenser shocks applied during the vulnerable phase of ventricular systole," Amer. J. Physiol., vol. 128, pp. 500-505, 1939.
3. A. Cimponeriu, C. F. Starmer, and A. Bezerianos, "A theoretical analysis of acute ischemia and infarction using ECG reconstruction on a 2-D model of myocardium," IEEE Trans. Biomed. Eng., vol. 48, pp. 41-54, Jan. 2001.
4. C. Luo and Y. Rudy, "A model of the ventricular cardiac action potential. Depolarization, repolarization, and their interaction," Circ. Res., vol. 68, pp. 1501-1526, 1991.
5. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators, "Preliminary report: Effect of encaidine and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction," N. Eng. J. Med., no. 321, pp. 406-410, 1989.
6. Cardiac Arrhythmia Suppression Trial II Investigators, "Ethmozine exerts an adverse effect on mortality in survivors of acute myocardial infarction," N. Eng. J. Med., no. 327, pp. 227-233, 1992.
7. J. L. Anderson, A. P. Hallstrom, A. E. Epstein, S. L. Pinski, Y. Rosenberg, M. O. Nora, D. Chilson, D. S. Cannon, R. Moore, and the AVID Investigators, "Design and results of the Antiarrhythmimics vs Implantable Defibrillators (AVID) registry," Circulation, vol. 99, pp. 1692-1699, 1999.
8. Y. Yamanouchi, Y. Cheng, P. J. Tchou, and I. R. Efimov, "The mechanisms of the vulnerable window: the role of virtual electrodes and shock polarity," Can. J. Physiol. Pharmacol., vol. 79, pp. 25-33, 2001.
9. F. A. Ehlert and J. J. Goldberger, "Cellular and pathophysiological mechanisms of ventricular arrhytmias in acute ischemia and infarction," Pacing Clin. Electrophysiol., vol. 20, no. 4, pp. 966-975, 1997.
10. C. F. Starmer, "Theoretical characterization of ion channel blockade: Ligand binding to periodically accessible receptors," J. Theoretical Biol., no. 119, pp. 235-249, 1986.
11. -, "Characterizing activity-dependent processes with a piecewise exponential model," Biometrics, no. 44, pp. 549-559, 1988.
12. A. O. Grant, D. W. Whalley, and D. J. Wendt, "Pharmacology of the cardiac sodium channel," in Zipes & Jalife. Cardiac Electrophysiology - From Cell to Bedside, 2nd ed. Philadelphia, PA: Saunders, 1995, ch. 24.
13. D.P. Zipes and J. Jalife, Cardiac Electrophysiology - From Cell to Bedside, 2nd ed. Philadelphia, PA: Saunders, 1995.
14. J. Wu and D. P. Zipes, "Effects of spatial segmentation in the continuous model of excitation propagation in cardiac muscle," J. Cardiovasc. Electrophysiol, vol. 10, no. 7, pp. 965-972, 1999.
15. H. A. Fozzard and M. Schoenberg, "Strength-duration curves in cardiac Purkinje fibers: Effects of liminal length and charge distribution," J. Physiol. London, vol. 226, pp. 593-618, 1972.
16. N. Maglaveras, F. Offner, F. J. L. van Capelle, M. A. Allessie, and A. V. Sahakian, "Effects of barriers on propagation of action potentials in two-dimensional cardiac tissue - A computer simulation study," J. Electrophysiol., vol. 28, no. 1, pp. 17-31, 1995.
17. A. T. Winfree, "Varieties of spiral wave behavior: An experimentalist's approach to the theory of excitable media," Chaos, vol. 1, pp. 303-334, 1991.
18. N. Maglaveras, A. V. Sahakian, and G. A. Myers, "Boundary conditions in cardiac propagating action potentials," IEEE Trans. Biomed. Eng., vol. 35, pp. 755-758, Sept. 1988.
19. C.F. Starmer, V. N. Biktashev, D. N. Romashko, M. R. Stepanov, O. N. Makarova, and V. I. Krinsky, "Vulnerability in an excitable medium: Analytical and numerical studies of initiating unidirectional propagation," Biophys. J., no. 65, pp. 1775-1787, 1993.
20. C. F. Starmer, A. R. Lancaster, A. A. Lastra, and A. O. Grant, "Cardiac instability amplified by use-dependent Na channel blockade," Amer. Physiol. Soc., pp. H1305-H1310, 1992.
21. B. J. Scherlag and R. Lazzara, "Arrhythmogenic effects of antiarrhythmic drugs," in Zipes & Jalife. Cardiac Electrophysiology - From Cell to Bedside, 2nd ed. Philadelphia, PA: Saunders, 1995, ch. 48.
22. D. M. Roden and K. T. Murray, "Pharmacokinetics, pharmacodynamics, and pharmacogenetics," in Zipes & Jalife. Cardiac Electrophysiology - From Cell to Bedside, 2nd ed. Philadelphia, PA: Saunders, 1995, ch. 111.
23. A. G. Kleber, "Resting membrane potential, extracellular potassium activity and intracellular sodium activity during acute global ischemia in isolated perfused guinea pig hearts," Circ. Res., vol. 52, pp. 442-450, 1983.
24. R. M. Shaw and Y. Rudy, "Electrophysiologic effects of acute myocardial ischemia: a theoretical study of altered cell excitability and action potential duration," Cardiovasc. Res., vol. 35, pp. 256-272, 1997.
25. R. M. Berne and M. N. Levy, Physiology. Washington, DC: Mossby, 1988.
26. N. Sperelakis, Cell Physiology - Source Book. New York: Academic, 1995.
27. C. F. Starmer and J. Starobin, "Spiral tip movement: The role of the action potential wavelength in polymorphic cardiac arrhythmias," Int. J. Bifurcation Chaos, vol. 6, no. 10, pp. 1909-1923, 1996.
28. B. N. Singh, "Pharmacologically controlling arrhythmias: To delay conduction or to prolong refractoriness," in Zipes & Jalife. Cardiac Electrophysiology - From Cell to Bedside, 2nd ed. Philadelphia, PA: Saunders, 1995, ch. 117.
29. M. S. Stanton, "Class I antiarrhythmic drugs: Quinidine, procainamide, disopyramide, lidocaine, mexiletine, tocainide, phenytoin, moricizine, flecainide, propafenone," in Zipes & Jalife. Cardiac Electrophysiology - From Cell to Bedside, 2nd ed. Philadelphia, PA: Saunders, 1995, ch. 112.